188 related articles for article (PubMed ID: 31281485)
1. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients.
Yun S; Park Y; Moon S; Ahn S; Lee K; Park HJ; Lee HS; Choe G; Lee KS
J Cancer; 2019; 10(13):3070-3078. PubMed ID: 31281485
[TBL] [Abstract][Full Text] [Related]
2. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles.
Chuang IC; Jang CS
Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
5. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
7. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
[No Abstract] [Full Text] [Related]
8. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
9. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
Yoneta D; Kato J; Kamiya T; Horimoto K; Sato S; Sawada M; Minowa T; Hida T; Sugita S; Uhara H
Int J Clin Oncol; 2022 Aug; 27(8):1364-1371. PubMed ID: 35650364
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
Cancer Manag Res; 2017; 9():741-750. PubMed ID: 29238224
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
Kim R; Coppola D; Wang E; Chang YD; Kim Y; Anaya D; Kim DW
Oncotarget; 2018 May; 9(34):23366-23372. PubMed ID: 29805739
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
[TBL] [Abstract][Full Text] [Related]
16. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
17. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
Duverger L; Osio A; Cribier B; Mortier L; De Masson A; Basset-Seguin N; Lebbé C; Battistella M
Cancer Immunol Immunother; 2019 Jun; 68(6):951-960. PubMed ID: 30953116
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Lin G; Fan X; Zhu W; Huang C; Zhuang W; Xu H; Lin X; Hu D; Huang Y; Jiang K; Miao Q; Li C
Oncotarget; 2017 Oct; 8(48):83986-83994. PubMed ID: 29137398
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
